WO2024144679 - A TABLET FORMULATION COMPRISING SELEXİPAG
National phase entry is expected:
Publication Number
WO/2024/144679
Publication Date
04.07.2024
International Application No.
PCT/TR2023/051692
International Filing Date
26.12.2023
Title **
[English]
A TABLET FORMULATION COMPRISING SELEXİPAG
[French]
FORMULATION EN COMPRIMÉ COMPRENANT DU SELEXİPAG
Applicants **
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Inventors
SUNEL, Fatih
PEHLIVAN AKALIN, Nur
ATAK, Fadime Bilgehan
TUNC, Guldeniz
Priority Data
2022/020995
28.12.2022
TR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
Turkpatent
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2072 | |
| EPO | Filing, Examination, Granting | 9171 | |
| Japan | Filing, Examination, Granting | 2124 | |
| South Korea | Filing, Examination, Granting | 2071 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,178
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a tablet formulation comprising selexipag or crystalline polymorph thereof and at least one binder, wherein binder has a d (0.9) particle size between 15 µm to 250 µm. Furthermore, the tablet is obtained using an effective process.[French]
La présente invention concerne une formulation en comprimé comprenant du selexipag ou un polymorphe cristallin de celui-ci et au moins un liant, le liant ayant une taille de particule d (0,9) comprise entre 15 µm et 250 µm. En outre, le comprimé est obtenu à l'aide d'un procédé efficace.